Navigation Links
Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
Date:7/24/2008

SHELTON, Conn., July 24 /PRNewswire/ -- Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park Bioventures, and included participation by Connecticut Innovations. Previous investors participating in the round included; Ascent Biomedical Ventures, Mitsubishi International Corporation and Wistar Morris. In conjunction with the financing, Dr. Christopher Moller, General Partner at Devon Park Bioventures, will join Cara's Board of Directors. The additional funds will be used primarily for further clinical development of both intravenous and oral formulations of Cara's second generation peripherally-selective kappa opioid agonist, CR845.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intravenous, subcutaneous, or oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing or elicit signs of addiction in animal models. CR845 is currently completing Phase Ia studies.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreenTM technology.

Forward-Looking Sta
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...wire-FirstCall/ -- eResearchTechnology, Inc.,(eRT...lized ECG and eClinical,technology, ePRO and othe...medical device and related industries, announced t...President and Chief Executive Officer, and Keith,...e scheduled to present at,the Piper Jaffray Healt...
(Date:12/2/2008)...wswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical,...nd supplier,of modernized traditional Chinese med...unced the implementation of a new sales and market...hospital clients into three classes in order,to o... The new strategy has classified distributors i...
(Date:12/2/2008)...RNewswire/ -- GeneGo, Inc., the leading systems bi...has become a certified GeneGo Center of Excellence...ccess to GeneGo,s MetaCore data analysis suite, tr...e is a world-class biomedical research facility ru...ut many departments, including research in cancer,...
(Date:12/2/2008)..., December 2 NicOx S.A.,... signed an agreement with,DSM for the commercial ...ce,(or API, active pharmaceutical ingredient). Na...and the first compound in the,Cyclooxygenase-Inhi...i-inflammatory agents, which recently achieved pos...
Breaking Biology Technology:eResearchTechnology, Inc. to Present at the Piper Jaffray Health Care Conference on December 2, 2008 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 3The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4
...y Systems Inc. said it has raised $1.4 million in... , ,The company, now about a year old, is developi...generating and using hydrogen fuel in car engines.... method involves generating it from water and suga...ve a chemical reaction. , ,The firm said Advantage...
Culver,s, a fast-food chain native to Wisconsin, is working with Madison Environmental Group on a kit to make cars run on old frying oil. Meanwhile, online extortionists are holding personal files fo
...t tolerating unexpected difference. The boxes tend...a spike in their power curve or an unanticipated c... us that way. The difference, of course, is our ab...e recognize it and choose to do something about it...ok like their pets. Do we begin to look like, act ...
...rket failed to reach double-digit growth in 2004 f... for this focused on concerns over drug safety, pr...products had their patents expire. , ,Let,s take a...the estimates of IMS Health, a pharmaceutical mark...e pharmaceutical market slowed down, one important...
Other Biology Technology:Machine like me 2Machine like me 3Though pharma growth slides, blockbusters reach new record 2Though pharma growth slides, blockbusters reach new record 3
(Date:12/1/2008)...D, Calif. Scientists around the world may benefit...online, that will help them to home in on the part..., Arend Sidow, PhD, associate professor of pathol...ool of Medicine, recently launched the novel bioin...de to determining the role different proteins play...
(Date:12/1/2008)...National Academy of Sciences will hold a colloquiu...es of the nature of niches of organisms. Leading r...predict future patterns of distribution and even e...ology, phylogenetics, and biodiversity informatics...of the Sackler Colloquium series, the event will t...
(Date:12/1/2008)...r, CO, USA The December Geosphere , The Geologic...Topics include detailed data integration from mult...dimentology, and paleontology, to study the southw...ion years ago; sedimentation in a piggyback basin;..., Nevada; and a study of the South Balkan extensio...
(Date:12/1/2008)...IDENCE, R.I. [Brown University] Gray mold is a ga...scientific name Botrytis cinerea , is a scourge t...species, including staples such as tomatoes, straw... endive, peas, peppers, and potatoes. Gray mold en...oxin that poisons the host plants, cells, eventual...
Breaking Biology News(10 mins):Powerful online tool for protein analysis provided pro bono by Stanford geneticist 2Powerful online tool for protein analysis provided pro bono by Stanford geneticist 3December Geosphere media highlights 2December Geosphere media highlights 3Brown chemist finds gray mold's killer gene 2CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 1CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 2CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 3CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008 8564 4Angiotech Announces Webcast and Call in Numbers for Annual and Special General Meeting of Shareholders 8561 1Johnson 26 Johnson Pharmaceutical Research 26 Development L L C Submits New Drug Application to FDA for Carisbamate 8559 1Johnson 26 Johnson Pharmaceutical Research 26 Development L L C Submits New Drug Application to FDA for Carisbamate 8559 2Johnson 26 Johnson Pharmaceutical Research 26 Development L L C Submits New Drug Application to FDA for Carisbamate 8559 3Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3332 1Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3332 2Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3332 3
..., a director at the Max Planck Institute of Bioche...the beginning of the 1990s that blocking blood ves... and shrinks its tissue. This fundamental principl...ingredient is Sunitinib. SUTENT® was recently appr... is expected to be brought onto the German market ...
...Comprehensive Cancer Center say that just one, sin...e cancer in mice. The discovery offers new insight...d lymphoma and at the same time underscores the po... RNA play in cell signaling pathways active in car...s is the first direct evidence that overexpression...
...ysed rocks from seabeds millions of years old. Car...ass 12 (99 percent) and atomic mass 13 (1 percent)...were characterised by a relatively strong increase...sed by a sudden large-scale release of carbon from...s. , The atmospheric carbon dioxide concentration...
...ept at blending in with their surroundings, cuttle...terns and can switch between them almost instantan...entists, to appear in the May 2006 issue of the jo...asters of disguise change their appearance based o...olorblind. , While previous research has reported ...
Other Biology News:Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4Single microRNA causes cancer in transgenic mouse 2Single microRNA causes cancer in transgenic mouse 3Carbon cycle was already disrupted millions of years ago 2Cuttlefish masters of disguise despite colorblindness 2
...esign, The Bioactive peptides are molecules of pe... behaviour or activity which can be developed at t..., chemical and agro-food applications. In this way...uperior properties for therapeutic applications. P...
... Bovine IFNγ ELISPOT (enzyme-lined immunospo...uction at the single cell level. A spot forms at t...ed (either using a dissection microscope or automa...r of cells added to the microplate. This allows th...
... Frame DNAscope is an integrated confocal laser sc...eadily integrated into your specific application. ...or we can tailor the system to your specifications...ing design has been modularized and built onto an ...
...Pix Professional 4200A can be upgraded to the Gene...matically loads, scans, analyzes, and saves result...when the batch is complete. Line-by-line autofocus...d slides. GenePix Pro gives you complete flexibili...
Biology Products: